Literature DB >> 17653127

What does the future hold for cell-based tolerogenic therapy?

Jeffrey A Bluestone1, Angus W Thomson, Ethan M Shevach, Howard L Weiner.   

Abstract

Evidence from animal models has shown that the transfer of regulatory T cells or tolerogenic dendritic cells can prevent or cure transplant rejection or re-establish self-tolerance in autoimmune disease. The potential of these tolerogenic cells for the treatment of T-cell-mediated diseases in humans has gained momentum in recent years. Here, Nature Reviews Immunology asks four leading researchers to provide their view on the future of cell-based tolerogenic therapy and to highlight some important issues that must be considered before this form of immunotherapy can become a reality.

Entities:  

Mesh:

Year:  2007        PMID: 17653127     DOI: 10.1038/nri2137

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  57 in total

1.  Inflammation: TREG cell control of autoimmune inflammation: a matter of timing?

Authors:  Hendrik Schulze-Koops; Alla Skapenko
Journal:  Nat Rev Rheumatol       Date:  2010-11       Impact factor: 20.543

2.  Eomesodermin(lo) CTLA4(hi) Alloreactive CD8+ Memory T Cells Are Associated With Prolonged Renal Transplant Survival Induced by Regulatory Dendritic Cell Infusion in CTLA4 Immunoglobulin-Treated Nonhuman Primates.

Authors:  Mohamed B Ezzelarab; Lien Lu; Hao Guo; Alan F Zahorchak; William F Shufesky; David K C Cooper; Adrian E Morelli; Angus W Thomson
Journal:  Transplantation       Date:  2016-01       Impact factor: 4.939

Review 3.  Advancements in immune tolerance.

Authors:  Ping-Ying Pan; Junko Ozao; Zuping Zhou; Shu-Hsia Chen
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

Review 4.  Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?

Authors:  Arthur A Vandenbark; Halina Offner
Journal:  Immunology       Date:  2008-09       Impact factor: 7.397

5.  Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses.

Authors:  A Anderson; C L Martens; R Hendrix; L L Stempora; W P Miller; K Hamby; M Russell; E Strobert; B R Blazar; T C Pearson; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2008-09-17       Impact factor: 8.086

6.  Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity.

Authors:  Akshata Udyavar; Rajshekhar Alli; Phuong Nguyen; Lesley Baker; Terrence L Geiger
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

7.  Regulatory allospecific T cell clones abrogate chronic allograft rejection.

Authors:  Ana Maria Waaga-Gasser; Martin R Grimm; Jens Lutz; Volkmar Lange; Susanne M Lenhard; Beatriz Aviles; Joana E Kist-van Holthe; Tatiana Lebedeva; Dimitry Samsonov; Detlef Meyer; Wayne W Hancock; Uwe Heemann; Martin Gasser; Anil Chandraker
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

8.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

Authors:  Dat Q Tran; John Andersson; Donna Hardwick; Lolita Bebris; Gabor G Illei; Ethan M Shevach
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

9.  An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.

Authors:  D Ly; R Tohn; B Rubin; H Blumenfeld; G S Besra; N Veerapen; S A Porcelli; T L Delovitch
Journal:  Clin Exp Immunol       Date:  2009-12-15       Impact factor: 4.330

10.  Allostimulatory activity of bone marrow-derived plasmacytoid dendritic cells is independent of indoleamine dioxygenase but regulated by inducible costimulator ligand expression.

Authors:  Bridget L Colvin; Tina L Sumpter; Daisuke Tokita; Jennifer Salati; Andrew L Mellor; Angus W Thomson
Journal:  Hum Immunol       Date:  2009-02-03       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.